Jazz Pharmaceuticals (NASDAQ:JAZZ) Upgraded at UBS Group

UBS Group upgraded shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) from a neutral rating to a buy rating in a research note released on Friday morning, MarketBeat reports. The firm currently has $179.00 price target on the specialty pharmaceutical company’s stock, up from their prior price target of $145.00.

JAZZ has been the subject of several other research reports. Needham & Company LLC reiterated a “buy” rating and issued a $210.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 5th. Morgan Stanley upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $140.00 to $175.00 in a research note on Thursday, December 12th. Truist Financial increased their target price on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research note on Thursday. TD Cowen reduced their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $189.40.

Jazz Pharmaceuticals Stock Up 1.7 %

JAZZ stock opened at $138.81 on Friday. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals has a 52-week low of $99.06 and a 52-week high of $148.06. The company has a 50-day moving average of $128.14 and a two-hundred day moving average of $120.07. The stock has a market capitalization of $8.43 billion, a price-to-earnings ratio of 19.55, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44.

Insider Transactions at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the completion of the sale, the chief executive officer now owns 439,744 shares of the company’s stock, valued at $53,785,088.64. This trade represents a 0.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CMO Robert Iannone sold 7,080 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00. Following the completion of the sale, the chief marketing officer now directly owns 82,024 shares of the company’s stock, valued at approximately $11,368,526.40. This represents a 7.95 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 25,193 shares of company stock valued at $3,533,122. Corporate insiders own 4.20% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Mackenzie Financial Corp increased its holdings in shares of Jazz Pharmaceuticals by 493.3% in the fourth quarter. Mackenzie Financial Corp now owns 20,286 shares of the specialty pharmaceutical company’s stock valued at $2,498,000 after purchasing an additional 16,867 shares in the last quarter. Forum Financial Management LP bought a new position in Jazz Pharmaceuticals in the fourth quarter valued at approximately $245,000. GF Fund Management CO. LTD. bought a new position in Jazz Pharmaceuticals in the fourth quarter valued at approximately $156,000. MidWestOne Financial Group Inc. boosted its stake in Jazz Pharmaceuticals by 10.4% in the fourth quarter. MidWestOne Financial Group Inc. now owns 24,347 shares of the specialty pharmaceutical company’s stock valued at $2,998,000 after acquiring an additional 2,284 shares during the last quarter. Finally, Elequin Capital LP boosted its stake in Jazz Pharmaceuticals by 677.8% in the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after acquiring an additional 183 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.